Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: zagnut1 who wrote (925)	3/28/2025 11:45:13 AM
From: Stanley Lake 92	3 Recommendations Recommended By erippetoe Huggenberg urslor Read Replies (2) \| Respond to of 1229

I see we now have a new conspiracy post. Damn, I accidentally touched the "recommend" and can't figure out how to remove. lol. As a follow up, I would note in that minute-plus transcript of PSS (16:40-17:48), he stated false science. If you know, it was obvious. Things like that do concern me. However, Anktiva's success, the mechanisms of the IL-15 receptor, and possibilities for other combined therapies for the platforms are not dependent on Dr. Soon-Shiong's direct work (albeit his ownership and funding matter greatly). If IBRX's deep research produces for other broader and different indications, it will be a huge success. That is to hope for and to follow the data and development cues. PSS is an overtly public and political figure. He's an insider now. Friends in high places might prove positive for IBRX? The science will, of course, be the primary determinant if Anktiva gets over the bar for NSCLC and the other cancers further down the path. GLTA until another time.